Skip to content

Fujian Province Cardiovascular Diseases Study

Fujian Province Cardiovascular Diseases Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02430025
Acronym
FJCVD
Enrollment
8000
Registered
2015-04-29
Start date
2015-06-30
Completion date
2020-05-31
Last updated
2015-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases

Keywords

Cardiovascular Diseases, Vascular Diseases, Acute Coronary Syndrome, Chest Pain, Heart Diseases, Myocardial Ischemia, Pathologic Processes

Brief summary

This proposal delineates a research plan to collect blood from the patients with cardiovascular diseases for the purpose of establishing a molecular biological bank registry. The Fujian provincial hospital will enroll 8,000 patients.The blood collected will be processed to create a repository of molecular biological plasma. Along with a sample of blood collected from individual patients, a concise general medical history, demographic data, electrocardiographic data, echocardiographic data, and laboratory data will be collected. A short interview will take place after enrollment during the outpatient visit or hospital stay, or may be conducted via phone call after enrollment. All the clinical data gathered will be compiled in Fujian provincial hospital center database, and would be stored in a format where a culmination of clinical findings, i.e. representing a disease of interest, can be used to search the database to identify the blood samples of all patients with such characteristics for further study.

Detailed description

The study is to commence on May 1st 2015 and is to be completed within 3-5 years. The targeted number of patients to be enrolled is 8,000. All patients have the history of cardiovascular diseases, will be eligible to be enrolled. Patients inclusion criteria are as follows, once informed consent is obtained: 1. Males or females at least 18 years old. 2. Patient has not been previously enrolled in the molecular biological bank registry of the Fujian provincial hospital. 3. Patient able to give informed consent. 4. Any patient with history of cardiovascular diseases (If a subject reports history of cardiovascular diseases at another facility, outside records will be obtained to confirm the diagnosis.

Interventions

None listed

Sponsors

Peking University
CollaboratorOTHER
Fujian Provincial Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18-80 year old males and non-child-bearing period females. * Clinical diagnosed with acute coronary syndrome including NSTE-ACS ,MI and STEMI. * Patients with STEMI((ST segment elevation myocardial infarction) and NSTEMI(non-ST segment elevation myocardial infarction) will be recruited within 48 hours of symptom onset. * Patients with cerebrovascular disease was made or confirmed by a board-certified neurologist with fellowship training in cerebrovascular disease and confirmed by standard diagnostic techniques such as head CT, MRI, MR angiography, CT angiography, carotid ultrasound, etc. * Sign the ICF(inform consent form)

Exclusion criteria

* child-bearing women * hypothyroidism, * active liver disease or dysfunction including agnogenic serum transaminase sustained elevation or higher than 3 times ULN(upper limit of normal) * severe anemia (hemoglobin,hematocrit \< 28%) * A history of psychiatric disorders * A history of jejunoileal bypass or gastric bypass surgery * Currently take steroids therapy * Diagnosed with malignant within 5 years * Severe renal function damage (creatinine clearance rate\<30 ml/min)

Design outcomes

Primary

MeasureTime frame
To further find some unknown small Metabolic molecules by mass spectrometry3-5 years

Contacts

Primary Contactyan so Guo, doctorate
ysguo1234@hotmail.com+8613509384950
Backup Contactxin ji Chen, doctorate
3319326@163.com+8613405927173

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026